|
Endometrial Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
|
14559803 |
2003 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer.
|
12569365 |
2003 |
|
Malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We postulate that the induction of Cdc25B expression in lung cancer cells by the ultimate carcinogen anti-BPDE accelerates the further development of lung carcinogenesis.
|
12591724 |
2003 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Nine genes were up-regulated in oesophageal adenocarcinoma tissue (matrix metalloproteinase 11 (MMP11), ornithine decarboxylase (ODC), cytokeratins 8 and 18, integrin alpha 3 (ITGA3), integrin alpha 6 (ITGA6), BIGH3 (transforming growth factor beta-induced), beta-catenin and CDC25B (M-phase inducer phosphatase 2)).
|
12680208 |
2003 |
|
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP.
|
12569365 |
2003 |
|
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP.
|
12569365 |
2003 |
|
Carcinoma of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We postulate that the induction of Cdc25B expression in lung cancer cells by the ultimate carcinogen anti-BPDE accelerates the further development of lung carcinogenesis.
|
12591724 |
2003 |
|
Primary malignant neoplasm of lung
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We postulate that the induction of Cdc25B expression in lung cancer cells by the ultimate carcinogen anti-BPDE accelerates the further development of lung carcinogenesis.
|
12591724 |
2003 |
|
Squamous cell carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
To identify pretreatment markers predicting response and survival, we examined the expression of cell cycle regulatory molecules, p53, p21(Waf1/Cip1) cyclin D1, and CDC25B, in biopsy specimens from 76 patients with stage III and stage IV squamous cell carcinoma.
|
15569370 |
2004 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The mechanism of resistance to HCC development is associated with nuclear accumulation of the cell cycle inhibitor p27(Kip1) protein and reduced expression of the Cdk1-activator Cdc25B phosphatase.
|
15082532 |
2004 |
|
Lymphoma
|
0.020 |
Biomarker
|
group |
LHGDN |
These findings suggest that i) cdc25B plays a role in the early phase of thyroid lymphoma possibly including the malignant transformation from chronic thyroiditis, and ii) cdc25A may contribute to the progression of lymphoma.
|
14767575 |
2004 |
|
Pancreatic carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
By quantitative RT-PCR, CDC25B mRNA was overexpressed in pancreatic cancer (7.5-fold) in comparison to the normal pancreas.
|
14712212 |
2004 |
|
Malignant neoplasm of pancreas
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
By quantitative RT-PCR, CDC25B mRNA was overexpressed in pancreatic cancer (7.5-fold) in comparison to the normal pancreas.
|
14712212 |
2004 |
|
Pancreatic Ductal Adenocarcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma.
|
14712212 |
2004 |
|
Thyroiditis
|
0.010 |
Biomarker
|
disease |
LHGDN |
Cdc25A and cdc25B expression in malignant lymphoma of the thyroid: correlation with histological subtypes and cell proliferation.
|
14767575 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25B is a cell-cycle regulatory protein, which is considered to be related to tumorigenesis and progression of tumours.
|
16803948 |
2006 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
CDC25B is a cell-cycle regulatory protein, which is considered to be related to tumorigenesis and progression of tumours.
|
16803948 |
2006 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of CDC25B was identified in 18 of the 19 glioblastomas, in 10 of the 17 anaplastic astrocytomas, but not in any of the 21 low-grade astrocytomas.
|
16803948 |
2006 |
|
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To elucidate the role of CDC25B in glioma, the expression of CDC25B and the association of the CDC25B expression with the clinicopathological parameters were investigated.
|
16803948 |
2006 |
|
Asthenozoospermia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The messenger RNA (mRNA) transcript level of CDC25B was increased in sperm samples of men with asthenospermia.
|
17336969 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CDC25B protein expression was categorized as positive in 59% (144 of 243) of ESCC cases on a tumor tissue microarray, and nonnegative LAMC2 patterns of protein expression were observed in 82% (225 of 275) of cases.
|
18559558 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Accordingly, increased expression of CDC25A and CDC25B is found in many high-grade tumors and is correlated with poor prognosis in human cancers.
|
19075563 |
2008 |
|
Squamous cell carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
|
18559558 |
2008 |
|
Squamous cell carcinoma
|
0.040 |
AlteredExpression
|
disease |
LHGDN |
Overexpression of CDC25B and LAMC2 mRNA and protein in esophageal squamous cell carcinomas and premalignant lesions in subjects from a high-risk population in China.
|
18559558 |
2008 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
CDC25B protein expression scores in subjects with esophageal biopsies diagnosed as normal (n = 35), dysplastic (n = 23), or ESCC (n = 32) increased significantly with morphologic progression.
|
18559558 |
2008 |